Also called: Parathyroid hormone (1-34) (human), Parathyroid Hormone (1-34), bovine, TIP 39, Tuberoinfundibular Neuropeptide, Parathyroid Hormone 2 Receptor Agonist
Parathyroid hormone is a natural substance your body makes in four tiny glands in your neck. These glands sit behind the thyroid gland. The hormone's main job is to control the amount of calcium in your blood. Calcium is a mineral your body needs for strong bones, working muscles, and healthy nerves.
When the calcium in your blood gets too low, the glands release this hormone. It tells your bones to release some stored calcium, tells your kidneys to hold onto calcium instead of flushing it out, and helps your body absorb calcium from food. Scientists have also made medicines from this hormone. These medicines are given as shots and can help build new bone in people whose bones are weak and break easily.
Most of what we know comes from studies of the injectable medicine, and its safety over very long use is still being studied. Researchers are also working on pill forms, because shots can be hard for people to take every day, but oral versions are still being tested. Anyone thinking about using it should talk to a doctor first, since changing calcium levels can be dangerous.
Benefits
The benefits people report — backed by research.
You just read the research on Parathyroid hormone. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
Safety
Adverse effects reported in the research and by community use.
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Evidence
Every claim above traces back to a source you can check — here are 1 of them.
Screening for parathyroid hormone resistance in patients with nonphenotypically evident pseudohypoparathyroidism
Timeline
Key moments in Parathyroid hormone’s research and regulatory timeline — sourced and dated.
News
Dated, sourced reporting that mentions Parathyroid hormone.
FDA approved Yorvipath (palopegteriparatide) injection for subcutaneous use in adults with hypoparathyroidism — the first FDA-approved hormone replacement for adults with the rare disorder. The approval drew on an 82-patient, 26-week trial in which 69% of Yorvipath patients versus 5% of placebo patients maintained normal calcium without active vitamin D or high-dose calcium supplements. The application received orphan drug designation and priority review; the drug was not studied in acute post-surgical hypoparathyroidism.
In this final notice, Takeda states that, in alignment with the US FDA, the NATPARA Special Use Program (SUP) closes on December 31, 2025, and no NATPARA shipments will be sent after that date. The letter follows the previously communicated global manufacturing discontinuation of NATPARA in December 2024. Prescribers are urged to develop alternate treatment plans for enrolled patients, including potential transition to the FDA-approved treatment for adult hypoparathyroidism (the letter links Yorvipath's prescribing information).
Fierce Pharma reports that Takeda is ending all manufacturing of Natpara for hypoparathyroidism in the US and abroad by the end of 2024 and will not return the drug to the US market, after a 2019 recall for rubber particulate fears and a Complete Response Letter from FDA. The story notes roughly 2,800 patients relied on Natpara before the recall and that the drug earned $230 million in 2018, its last full reported US sales year. Takeda said it cannot implement a solution to the rubber particle formation issue.
Wondering how Parathyroid hormone pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.